Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2001 2
2002 1
2003 1
2004 1
2005 1
2006 2
2007 1
2008 4
2009 7
2010 10
2011 9
2012 19
2013 26
2014 15
2015 15
2016 22
2017 26
2018 20
2019 10
2020 15
2021 16
2022 14
2023 10
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

217 results

Results by year

Filters applied: . Clear all
Page 1
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Castro Narro GE, Chowdhury A, Cortez-Pinto H, Cryer DR, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot BG, Korenjak M, Kowdley KV, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell EE, Roden M, Romero-Gómez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN; NAFLD Nomenclature consensus group. Rinella ME, et al. Hepatology. 2023 Dec 1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520. Epub 2023 Jun 24. Hepatology. 2023. PMID: 37363821 Free PMC article.
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, Eguchi Y, Geier A, Kondili LA, Kroy DC, Lazarus JV, Loomba R, Manns MP, Marchesini G, Nakajima A, Negro F, Petta S, Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg JM, Tacke F, Tanaka J, Trautwein C, Wei L, Zeuzem S, Razavi H. Estes C, et al. J Hepatol. 2018 Oct;69(4):896-904. doi: 10.1016/j.jhep.2018.05.036. Epub 2018 Jun 8. J Hepatol. 2018. PMID: 29886156 Free article.
Extrahepatic Manifestations of Chronic Viral C Hepatitis.
Petta S, Craxì A. Petta S, et al. Gastroenterol Clin North Am. 2020 Jun;49(2):347-360. doi: 10.1016/j.gtc.2020.01.012. Epub 2020 Mar 29. Gastroenterol Clin North Am. 2020. PMID: 32389367 Review.
Hepatits C virus (HCV) infection has been largely associated with extrahepatic comorbidities such as diseases related to dysregulation of the immune system, neuropsychiatric disorders, and cardiometabolic alterations. ...
Hepatits C virus (HCV) infection has been largely associated with extrahepatic comorbidities such as diseases related to dysregulatio …
Hepatitis C virus and cardiovascular: A review.
Petta S. Petta S. J Adv Res. 2017 Mar;8(2):161-168. doi: 10.1016/j.jare.2016.06.001. Epub 2016 Jun 18. J Adv Res. 2017. PMID: 28149651 Free PMC article. Review.
Chronic hepatitis C virus (HCV) infection is a systemic disease that leads to increased risks of cirrhosis and its complications, as well as extrahepatic disturbances, including immune-related disorders and metabolic alterations such as insulin resistance and steatosis. .. …
Chronic hepatitis C virus (HCV) infection is a systemic disease that leads to increased risks of cirrhosis and its complications, as …
Ethical assessment of hepatitis C virus treatment: The lesson from first generation protease inhibitors.
Sacchini D, Craxì L, Refolo P, Minacori R, Cicchetti A, Gasbarrini A, Cammà C, Spagnolo AG; WEF Study Group. Sacchini D, et al. Dig Liver Dis. 2015 May;47(5):351-5. doi: 10.1016/j.dld.2014.11.011. Epub 2014 Nov 24. Dig Liver Dis. 2015. PMID: 25534233 Review.
Since chronic hepatitis C has mostly become curable, issues concerning choice and allocation of treatment are of major concern. We assessed the foremost ethical issues in hepatitis C virus therapy with 1st generation protease inhibitors using the personalist ethical …
Since chronic hepatitis C has mostly become curable, issues concerning choice and allocation of treatment are of major concern. We as …
Metabolic factors and chronic hepatitis C: a complex interplay.
Macaluso FS, Maida M, Minissale MG, Li Vigni T, Attardo S, Orlando E, Petta S. Macaluso FS, et al. Biomed Res Int. 2013;2013:564645. doi: 10.1155/2013/564645. Epub 2013 Jul 17. Biomed Res Int. 2013. PMID: 23956991 Free PMC article. Review.
In the last years, several lines of evidence showed how metabolic factors may influence the natural history of patients with chronic hepatitis C. Chronic HCV infection is able to perturb the metabolic homeostasis of the host, in a context of complex interactions where pre- …
In the last years, several lines of evidence showed how metabolic factors may influence the natural history of patients with chronic hepatit …
Hepatitis C and diabetes: the inevitable coincidence?
Lonardo A, Adinolfi LE, Petta S, Craxì A, Loria P. Lonardo A, et al. Expert Rev Anti Infect Ther. 2009 Apr;7(3):293-308. doi: 10.1586/eri.09.3. Expert Rev Anti Infect Ther. 2009. PMID: 19344243 Review.
T2D and IR are independent predictors of a more rapid progression of liver fibrosis and impaired response to antiviral treatment in chronic hepatitis C. Patients with cirrhosis and T2D have an increased susceptibility to hepatic encephalopathy and hepatocellular carcinoma …
T2D and IR are independent predictors of a more rapid progression of liver fibrosis and impaired response to antiviral treatment in chronic …
Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies.
Petta S, Maida M, Macaluso FS, Barbara M, Licata A, Craxì A, Cammà C. Petta S, et al. Gastroenterology. 2016 Jan;150(1):145-155.e4; quiz e15-6. doi: 10.1053/j.gastro.2015.09.007. Epub 2015 Sep 18. Gastroenterology. 2016. PMID: 26386298 Review.
BACKGROUND & AIMS: There have been many studies of the effects of hepatitis C virus (HCV) infection on cardiovascular risk, but these have produced ambiguous results. ...
BACKGROUND & AIMS: There have been many studies of the effects of hepatitis C virus (HCV) infection on cardiovascular risk, but t …
Is global elimination of HCV realistic?
Calvaruso V, Petta S, Craxì A. Calvaruso V, et al. Liver Int. 2018 Feb;38 Suppl 1:40-46. doi: 10.1111/liv.13668. Liver Int. 2018. PMID: 29427499 Review.
The elimination of hepatitis C virus (HCV) has been made possible through the availability of new antiviral drugs which may now be administered to all patients with HCV infection, even those with decompensated cirrhosis. ...
The elimination of hepatitis C virus (HCV) has been made possible through the availability of new antiviral drugs which may now be ad …
PSD3 downregulation confers protection against fatty liver disease.
Mancina RM, Sasidharan K, Lindblom A, Wei Y, Ciociola E, Jamialahmadi O, Pingitore P, Andréasson AC, Pellegrini G, Baselli G, Männistö V, Pihlajamäki J, Kärjä V, Grimaudo S, Marini I, Maggioni M, Becattini B, Tavaglione F, Dix C, Castaldo M, Klein S, Perelis M, Pattou F, Thuillier D, Raverdy V, Dongiovanni P, Fracanzani AL, Stickel F, Hampe J, Buch S, Luukkonen PK, Prati D, Yki-Järvinen H, Petta S, Xing C, Schafmayer C, Aigner E, Datz C, Lee RG, Valenti L, Lindén D, Romeo S. Mancina RM, et al. Nat Metab. 2022 Jan;4(1):60-75. doi: 10.1038/s42255-021-00518-0. Epub 2022 Jan 31. Nat Metab. 2022. PMID: 35102341 Free PMC article.
217 results